TL;DR: US drugmaker Eli Lilly will invest more than $1 billion in India to expand manufacturing and set up a new hub in Hyderabad, creating jobs and boosting production of medicines like Mounjaro.
Investment and Expansion
Major Investment:
On October 6, 2025, Eli Lilly announced it will invest over $1 billion in India over the next few years to expand its manufacturing capacity and supply chain.
- New Hyderabad Hub:
- Job Creation:
- Medicines Focus:
- Existing Presence in India:
- Government Support:
- Global Strategy:
A manufacturing and quality hub will be set up in Hyderabad, serving as the oversight center for Lilly’s contract manufacturing network across India.
Hiring will begin immediately for roles in engineering, chemistry, analytical science, quality control, and management.
The investment will support production of key medicines for diabetes, obesity (including Mounjaro), Alzheimer’s, cancer, and autoimmune diseases.
Eli Lilly already operates in Gurugram, Bengaluru, and Hyderabad, employing over 1,400 professionals in research and development, IT, and data analytics.
Telangana Chief Minister A. Revanth Reddy welcomed the move, calling it a sign of Hyderabad’s role as a healthcare innovation hub.
Since 2020, Eli Lilly has invested over $55 billion globally to expand manufacturing in response to high demand for GLP-1 drugs like Mounjaro and Zepbound.